US drug prices are the highest among peer nations due to structural policy, not innovation costs

The claim

Americans pay dramatically more for prescription drugs than residents of any other wealthy country. The pharmaceutical industry and its defenders argue that this price premium reflects the cost of innovation: US patients are, in effect, subsidizing the global R&D enterprise. On this account, the high US prices are an unfortunate but necessary feature of a system that produces the world’s most important medicines. Price controls abroad are described as free-riding — foreign governments capturing innovation value without funding it. Remove US pricing freedom and the pipeline dries up.

The structural claim reverses this framing: the price gap is not produced by innovation economics but by deliberate policy choices that strip the US government of bargaining power, extend patent monopolies beyond their stated purpose, and allow manufacturers to extract rents unavailable anywhere else in the developed world.

The mechanism

Under the standard pharmaceutical business model, a company patents a molecule, receives 20 years of statutory exclusivity from the date of filing (usually filing occurs well before approval), and sets the launch price. In the US, that price is set by the manufacturer with no external constraint. Medicare, which covers 66 million Americans and is the single largest drug purchaser in the world, was explicitly prohibited from negotiating prices by Section 1860D-11(i) of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) — the non-interference clause. This was a legislated transfer of bargaining power from the public to manufacturers.

In every peer country, one of three structural mechanisms disciplines prices: (1) reference pricing, in which the government sets reimbursement based on the therapeutic comparator’s price (Germany’s AMNOG system); (2) health technology assessment with cost-effectiveness thresholds (UK’s NICE, with an approximately £20,000-£30,000/QALY threshold); or (3) direct price negotiation backed by the credible threat of formulary exclusion (France, Canada). All three mechanisms result in substantially lower prices than the US while maintaining manufacturer access to those markets — because some profit is better than none.

The innovation subsidy argument breaks down at the margins. Pharmaceutical companies do not price at cost-plus; they price at what each market will bear. In Germany, Pfizer charges what the AMNOG process permits. In the US, it charges what the absence of regulation allows. The willingness to enter regulated markets at lower prices demonstrates that those prices still exceed marginal cost and still allow profitable investment in R&D.

The mechanism for maintaining high US prices beyond initial patent terms involves three practices: evergreening, in which minor reformulations (extended-release, new delivery mechanism, new indication) extend patent protection and reset the exclusivity clock; patent thickets, in which companies file dozens of overlapping patents on a single drug (AbbVie filed 136 patents on Humira, extending effective exclusivity to 2034, nearly 20 years after the original compound patent expired); and pay-for-delay settlements, in which branded manufacturers pay generic competitors to delay market entry, sharing monopoly rents in exchange for eliminating price competition. The FTC estimated pay-for-delay settlements cost consumers $3.5 billion annually as of 2013.

The evidence

The RAND price comparison (2021)

The RAND Corporation’s Comparing Prescription Drug Prices in the United States and Other Countries (Mulcahy et al., 2021) is the most comprehensive direct comparison available. Using 2019 wholesale acquisition cost data for drugs sold in both the US and at least one of 32 comparison countries, RAND found US prices were 256% of the weighted average across all comparators — 2.56× peer-country prices. Broken down by country: Germany 81% of US; Canada 56%; UK 42%; France 41%; Japan 54% (figures represent foreign price as a share of US price). Brand-name drugs drove the differential most sharply: US brand prices were 344% of the international average. Generic prices were more comparable (84% of international average), which is consistent with the structural explanation — generics face actual price competition in the US; brands do not.

Public funding and the R&D subsidy claim

Chakravarthy et al. (2019), published in PNAS, found that NIH contributed to published research underlying every one of the 210 drugs approved by the FDA between 2010 and 2016, totaling more than $100 billion in public investment. Blume-Kohout and Sood (2013) estimated that NIH funding for basic science directly enables the discovery-phase research that pharmaceutical companies then develop into approved drugs. The implication is significant: the R&D that creates the molecule is substantially publicly funded, while the commercialization phase — formulation, trials, regulatory submission — is privately funded. Manufacturers’ pricing power covers both phases and their profits, but the foundational innovation investment is socialized while pricing gains are privatized.

Pharmaceutical companies’ own financial disclosures complicate the innovation narrative further. In 2022, the 14 largest US-listed pharmaceutical companies (by revenue) collectively spent $136 billion on R&D and $215 billion on selling, general and administrative expenses (SG&A), which includes marketing, executive compensation, and lobbying. AbbVie, whose primary product is Humira, spent $6.5 billion on R&D and $14.5 billion on SG&A in 2022. The ratio is not consistent with a company primarily constrained by innovation costs.

IQVIA launch price trends

IQVIA’s Institute for Human Data Science tracks drug launch prices annually. The median US list price for a newly approved drug rose from approximately $2,115 per year in 2008 to $180,007 per year in 2021 in constant dollars — an 85-fold increase in 13 years, against a backdrop of stable or declining scientific complexity per approved molecule. This trajectory is inconsistent with rising innovation costs driving prices; it is consistent with manufacturers pricing to the insurer’s willingness to pay in an unregulated market.

The non-interference clause as policy lever

The VA drug benefit, unlike Medicare Part D, has always permitted negotiation. A 2019 analysis by the HHS Assistant Secretary for Planning and Evaluation found that VA prices were 40-58% lower than Medicare Part D prices for the same drugs. The two programs cover overlapping populations and the same US clinical context. The price difference is entirely attributable to the presence or absence of negotiation authority — an internal natural experiment with no confounds from national income, disease burden, or cultural differences.

Germany’s AMNOG as the reference case

Germany’s Arzneimittelmarktneuordnungsgesetz (AMNOG), enacted in 2010, requires manufacturers to submit a benefit dossier for all new drugs at launch. The Federal Joint Committee (G-BA) assesses added benefit relative to the standard of care. If benefit is established, the manufacturer and the GKV-Spitzenverband (the statutory insurer federation) negotiate a price; if no benefit is established, the drug is reimbursed only at the level of the therapeutic comparator. Germany still receives most drugs the US receives; the time to market is slightly longer but access to innovative therapies is broadly maintained. German brand-name drug prices average approximately 81% of US prices (RAND 2021).

The Inflation Reduction Act (2022) as a policy experiment

The IRA’s Medicare Drug Price Negotiation Program, effective for the first 10 selected drugs in 2026, produced negotiated prices 38-79% below the pre-negotiation list price. Eliquis (apixaban, Bristol-Myers Squibb/Pfizer) was reduced from $521/month to $197/month — a 62% reduction. Januvia (sitagliptin, Merck) from $527/month to $113/month — a 79% reduction. None of the affected manufacturers withdrew the drug from the US market, consistent with the prediction that regulated prices still cover marginal cost and generate profit. The IRA applies only to a small number of high-expenditure drugs and only after extended exclusivity periods; it is a partial and lagged reform, but its early results confirm the structural analysis.

Who benefits

The non-interference clause in Medicare Part D was written by and for the pharmaceutical industry. The legislation passed in 2003 with the active lobbying of PhRMA (the Pharmaceutical Research and Manufacturers of America), whose member companies faced no binding US price constraint and had strong interest in maintaining that status. The pharmaceutical and health products sector spent $373 million lobbying Congress in 2022 (OpenSecrets) — the largest single-sector lobbying expenditure for that year. The top individual spenders included Pfizer ($12.8M), Amgen ($10.7M), AbbVie ($10.4M), and PhRMA ($29.4M as a trade association).

Pharmacy benefit managers (PBMs) — Express Scripts, CVS Caremark, OptumRx — operate as intermediaries between manufacturers and payers, negotiating rebates from manufacturers that are partially retained as revenue. The rebate system creates perverse incentives: PBMs have a financial interest in high list prices (from which rebates are calculated) and in excluding lower-priced biosimilars that generate smaller rebates. The three largest PBMs control approximately 80% of the US market and are vertically integrated with insurers and pharmacies, limiting competitive pressure.

Legislators on the Senate Finance and House Ways and Means committees receive disproportionate pharmaceutical industry donations, as documented by the Center for Responsive Politics. The non-interference clause has survived 20 years of reform efforts. Its persistence is not an oversight — it is a product of the lobbying expenditure designed to maintain it.

The counter

The innovation subsidy argument is not wholly without foundation. The US pharmaceutical system does produce a disproportionate share of first-in-class drug approvals, and high US margins do cross-subsidize global access to some degree. Europe has faced criticism for delayed access to certain cell and gene therapies, where NICE and HTA bodies have declined coverage at manufacturer-demanded prices, resulting in UK patients waiting years for treatments available in the US. The willingness to pay in the US does fund some clinical trials that might otherwise not occur.

The empirical question is whether the premium is proportionate to the innovation contribution. Kesselheim, Avorn, and Sarpatwari (2016) found that 72% of new drugs approved in a sample period offered no meaningful improvement over existing treatments; these drugs commanded high launch prices not justified by therapeutic advance. The Tufts Center for the Study of Drug Development’s widely cited $2.6 billion per-drug development cost estimate includes cost of capital and failures — a legitimate accounting — but has been criticized by Light and Warburton (2011) for methodological choices that inflate the figure. The actual out-of-pocket development cost for a new molecular entity, excluding capital charges, is estimated at $161-$985 million (DiMasi range), and much foundational research was publicly funded.

The IRA negotiations also raise a legitimate concern about incentive effects: if future revenue expectations are reduced by anticipated negotiation, some marginal drug development programs may be cancelled. This is a genuine trade-off. The counter-argument is that the current US price premium funds marginal drugs with minimal clinical benefit at the cost of access to essential medicines for the uninsured and underinsured — and that the trade-off is distributional as well as aggregate.

References

Mulcahy, A. W., Hlavka, J. P., & Case, S. R. (2021). Prescription drug prices in the United States are 2.56 times those in other countries. RAND Corporation. https://doi.org/10.7249/RR2956

Chakravarthy, R., Cotter, K., DiMasi, J., Milne, C.-P., & Wendel, N. (2019). Public and private sector contributions to the research and development of the most transformative drugs in the last 25 years: From theory to therapy. PNAS, 116(41), 20538–20543. https://doi.org/10.1073/pnas.1817752116

Blume-Kohout, M. E., & Sood, N. (2013). Market size and innovation: Effects of Medicare Part D on pharmaceutical research and development. Journal of Public Economics, 97, 327–336. https://doi.org/10.1016/j.jpubeco.2012.10.003

Kesselheim, A. S., Avorn, J., & Sarpatwari, A. (2016). The high cost of prescription drugs in the United States: Origins and prospects for reform. JAMA, 316(8), 858–871. https://doi.org/10.1001/jama.2016.11237

IQVIA Institute for Human Data Science. (2022). Global trends in R&D 2022: Activity, productivity, and enablers. IQVIA. https://www.iqvia.com/insights/the-iqvia-institute/reports/global-trends-in-r-and-d-2022

Light, D. W., & Warburton, R. (2011). Demythologizing the high costs of pharmaceutical research. BioSocieties, 6(1), 34–50. https://doi.org/10.1057/biosoc.2010.40

Centers for Medicare & Medicaid Services. (2023). Medicare drug price negotiation program: Negotiated prices for initial price applicability year 2026. CMS. https://www.cms.gov/inflation-reduction-act/medicare-drug-price-negotiation

Federal Trade Commission. (2013). Pay-for-delay: How drug company pay-offs cost consumers and taxpayers. FTC. https://www.ftc.gov/reports/pay-for-delay-how-drug-company-pay-offs-cost-consumers-and-taxpayers

DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 47, 20–33. https://doi.org/10.1016/j.jhealeco.2016.01.012

HHS Assistant Secretary for Planning and Evaluation. (2019). Comparing drug prices in the US to 16 OECD countries. ASPE Issue Brief. https://aspe.hhs.gov/reports/comparing-drug-prices-us-16-oecd-countries